| Literature DB >> 32365828 |
Natalia Manousi1, Paraskevas D Tzanavaras1, Constantinos K Zacharis2.
Abstract
In-tube solid phase microextraction is a cutting-edge sample treatment technique offering significant advantages in terms of miniaturization, green character, automation, and preconcentration prior to analysis. During the past years, there has been a considerable increase in the reported publications, as well as in the research groups focusing their activities on this technique. In the present review article, HPLC bioanalytical applications of in-tube SPME are discussed, covering a wide time frame of twenty years of research reports. Instrumental aspects towards the coupling of in-tube SPME and HPLC are also discussed, and detailed information on materials/coatings and applications in biological samples are provided.Entities:
Keywords: bioanalysis; in-tube; review; sample preparation; separation; solid phase microextraction
Mesh:
Year: 2020 PMID: 32365828 PMCID: PMC7248733 DOI: 10.3390/molecules25092096
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1General graphical representation of in-tube SPME setups. (A) “Draw-inject” mode; (B) “in-valve” mode. It should be noted that the analytical column can be omitted in certain in-tube SPME-MS applications.
Figure 2Materials and coatings used in in-tube SPME applications.
Figure 3(A) Schematic representation of the fabrication process of a polythiophene/graphene (PTh/GO) nanostructured electrodeposited coating using a peristaltic pump. (B) Internal surface of stainless steel tube after coating. Adopted from [103] with permissions.
Bioanalytical HPLC applications of in-tube SPME for the determination of drugs.
| Analyte | Sample | SPME Material | SPME Mode | Detection | LOD/LOQ | Year | Ref |
|---|---|---|---|---|---|---|---|
| Cannabidiol, Δ9-tetrahydrocannabinol | Human plasma | Dummy molecularly | In-valve | MS/MS | NM 1/10 ng mL−1 | 2020 | [ |
| Chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites | Human | Butyl methacrylate-co-ethylene glycol | In-valve | MS/MS | NM/10 ng mL−1 | 2019 | [ |
| Anandamide, 2-arachidonoyl glycerol | Human | Polymeric ionic liquid open tubular capillary column | In-valve | MS/MS | NM/0.05, 0.10 ng mL−1 | 2019 | [ |
| Amino acids, neurotransmitters | Human | Dual ligand sol–gel organic-silica hybrid | In-valve | MS/MS | NM/6–360 nmol mL−1 | 2019 | [ |
| Ketoprofen, flurbiprofen, diclofenac | Human plasma | Poly(deep eutectic solvent) | In-valve | UV | 0.05–0.5/0.2–2 ng mL−1 | 2018 | [ |
| Losartan | Human plasma, | Polypyrrole-deep eutectic solvent coated capillary | In-valve | UV | 0.2, 0.5 μg L−1/NM | 2018 | [ |
| Jatorrhizine, palmatine, berberine | Rat plasma | immobilized | In-valve | MS/MS | 0.1–0.3 pg mL−1 | 2017 | [ |
| Amitriptyline, imipramine, chlorpromazine | Human plasma | indole-thiophene copolymer nanocomposite | In-valve | UV | 40 ng mL−1/80 ng mL−1 | 2017 | [ |
| Amitriptyline, doxepin | Human plasma, | Polythiophene/graphene oxide (PTh/GO) nanostructured coating | In-valve | UV | 0.3, 0.5/2.3, 2.9 ng mL−1 | 2016 | [ |
| Sulfadiazine, sulfadimidine, sulfamethoxazole | Rat plasma | Poly(3,4-ethylenedioxythiophene) | In-valve | UV | 0.002–0.05/0.01–0.25 ng mL−1 | 2016 | [ |
| Berberine, palmatine, jatrorrhizine | Rat plasma | Poly(acrylamide–ethylene glycol dimethacrylate)monolith | In-valve | UV | 0.01/0.03 ng mL−1 | 2013 | [ |
| Glycoproteins | Rat plasma | Poly(vinylphenylboronic acid–ethylene glycol dimethacrylate) monolithic material | In-valve | UV | 0.01 μg mL−1/NM | 2018 | [ |
| Interferon alpha 2a | Human plasma | Molecularly imprinted polymer | Draw-inject | FLD | NM/8 ng mL−1 | 2013 | [ |
| Interferon alpha 2a | Human plasma | Monoclonal anti-interferon 2a antibody | Draw-inject | FLD | NM/0.006 MIU mL−1 | 2013 | [ |
| Ketoprofen, fenbufen, ibuprofen | Human plasma | Poly(4-vinylpyridine-co-ethylene dimethacrylate) monolith | In-valve | UV | 2.01–4.77/6.70–15.9 ng mL−1 | 2012 | [ |
| Lidocaine and its metabolite | Human plasma | 14% cyanopropylphenyl methylpolysiloxane | Draw-inject | UV | 15, 20/50 ng mL−1 | 2012 | [ |
| Rifampicin | Human plasma | Polyethylene glycol | Draw-inject | UV | MN/0.1 μg mL−1 | 2011 | [ |
| Interferon alpha 2a | Human plasma | Restricted access material | Draw-inject | FLD | NM/0.06 MIU mL−1 | 2011 | [ |
| Antidepressants | Human plasma, urine | Hybrid organic–inorganic silica monolith with cyanoethyl functional groups | In-valve | MS | 0.06–2.84/0.19–9.45 ng mL−1 | 2010 | [ |
| Fluoxetine, norfluoxetine | Human plasma | Polypyrrole-coated capillary | Draw-inject | RF | NM/10–15 ng mL−1 | 2009 | [ |
| Moperone, floropipamide, haloperidol, spiroperidol, bromperidol, pimozide | Human plasma | DB-17 | Draw-inject | MS/MS | 0.03–0.2/0.1–0.5 ng mL−1 | 2009 | [ |
| Mirtazapine, citalopram, paroxetine, duloxetine, fluoxetine, sertraline | Human plasma | OV-1701 | Draw-inject | UV | 5–20/20–50 ng mL−1 | 2008 | [ |
| Candesartan, losartan, irbesartan, valsartan, telmisartan | Human plasma, urine | Poly(MAA-EGDMA) monolithic | In-valve | FLD | 0.1–15.3/0.4–51 ng mL−1 | 2005 | [ |
| Camptothecin, 10-hydroxycamptothecin | Human plasma | Poly(MAA-EGDMA) monolithic capillary column | In-valve | UV | 1.79–2.62/5.96–8.73 ng mL−1 | 2005 | [ |
| Verapamil metabolites | Human plasma, urine | Polypyrrole-coated capillary | Draw-inject | UV, MS | 52–83 ng mL−1 (UV), 5–8 ng mL−1 (MS)/NM | 2002 | [ |
| Indomethacin | Human plasma, urine, blood | Nanostructured copolymer coating consisting of polypyrrole doped with ethylene glycol dimethacrylate | In-valve | UV | 0.6–2.0 μg L−1/NM | 2016 | [ |
| Theobromine, theophylline, caffeine | Human serum | Poly(methacrylic acid–ethylene glycol dimethacrylate) monolithic | In-valve | UV | 6.5–12.0/21.5–39.6 ng mL−1 | 2004 | [ |
| Oxazepam, temazepam, nordazepam, diazepam | Human serum | Restricted access material (RAM), alkyl-diol-silica (ADS), | Draw-inject | UV | 22–29/74–98 ng mL−1 | 2002 | [ |
| Fluoxetine | Human serum | Immunoaffinity-based (BSA-fluoxetine conjugate) | Draw-inject | MS | NM/5 ng mL−1 | 2007 | [ |
| Glycoprotein | Human serum | Boronate-functionalized molecularly imprinted monolithic column | In-valve | UV | NM | 2013 | [ |
| Theobromine, paraxanthine, theophylline, caffeine | Human serum | ZB-FFAP (100% nitroterephthalic modified polyethylene glycol). | In-valve | UV | 0.1–0.5/0.4–1.5 μg mL−1 | 2020 | [ |
| Benzodiazepines | Human serum, urine | Supelco-Q plot capillary column | Draw-inject | MS | 0.02–2/0.5–2 ng mL−1 | 2000 | [ |
| Beta-blockers | Human serum, urine | Omegawax 250 capillary | Draw-inject | MS | 0.1–1.2 ng mL−1/NM | 1999 | [ |
| Stimulants, beta-blockers | Human serum, urine | Omegawax 250 capillary | Draw-inject | MS | 0.1–1.2 ng mL−1/NM | 2000 | [ |
| Propranolol | Human serum | Molecularly imprinted polymer | Draw-inject | UV | 0.32 μg mL−1 | 2001 | [ |
| 17β-Estradiol, estrone, ethinyl estradiol, progesterone, estriol | Human urine | NH2-MIL-53(Al)-polymer monolithic column | In-valve | UV-FLD | 0.002–0.04 μg L−1/NM | 2017 | [ |
| Naproxen | Human urine | Polypyrrole (PPy)-coated | In-valve | UV | 0.07 μg L−1 | 2015 | [ |
| Moxifloxacin | Human urine | Fe3O4 nanoparticles-packed | In-valve | UV | 0.03 μg L−1/NM | 2015 | [ |
| Ciprofloxacin, enrofloxacin, ofloxacin | Human urine | Sodium dodecyl sulfate coated Fe3O4 nanoparticles | In-valve | UV | 0.01–0.05 μg L−1 | 2015 | [ |
| Dopamine, 5-hydroxytryptamine | Human urine | Boronate affinity solid phase microextraction | In-valve | MS/MS | 1.2/4.0 ng mL−1 | 2010 | [ |
| Nicotine, cotinine, nornicotine, anabasine, anatabine | Human urine, saliva | CP-Pora PLOT amine capillary column | Draw-inject | MS | 0.015–0.040 ng mL−1/NM | 2009 | [ |
| Ketoprofen, fenbufen, ibuprofen | Human urine | Beta-cyclodextrin coated capillary column | Draw-inject | UV | 18–38 ng mL−1/NM | 2005 | [ |
| Ketamine | Human urine | Poly(methacrylic acid- ethylene glycol dimethacrylate) monolithic capillary | In-valve | UV | 6.4 ng mL−1/NM | 2004 | [ |
| Stimulants | Human urine, hair | Polypyrrole coated capillary column | Draw-inject | MS | 8–56 ng L−1/NM | 2001 | [ |
| Diclofenac, mefenamic acid | Human urine, plasma | Nanostructured polypyrrole | In-valve | UV | 0.08–1.6 μg L−1/NM | 2018 | [ |
| Urinary biomarkers (8-isoprostane, 8-hydroxy-2′-deoxyguanosine, 3-nitro-L-tyrosine) | Human urine | Carboxen | Draw-inject | MS/MS | 3.4–21.5 pg mL−1/0.02 ng mL−1 | 2018 | [ |
| Heterocyclic amines | Human urine | Supel-Q PLOT capillary column | Draw-inject | MS/MS | NM/1.7–4.1 pg mL−1 | 2014 | [ |
| 8-hydroxy-2′-deoxyguanosine, 3-hydroxyphenanthrene, 1-hydroxypyrene | Human urine | Graphene oxide, poly(3,4-ethylenedioxythiophene), poly- pyrrole | In-valve | MS | 0.004–0.041/0.016–0.135 ng mL−1 | 2019 | [ |
| 8-hydroxy-2′-deoxyguanosine | Human urine | Carboxen 1006 PLOT capillary column | Draw-inject | MS/MS | 8.3 pg mL−1/NM | 2016 | [ |
| Perphenazine, chlorpromazine | Human urine, plasma | nanostructured | In-valve | UV | 0.2–0.8 μg L−1/NM | 2018 | [ |
| Nornicotine, anatabine, anabasine, nicotine, cotinine | Human urine, saliva | CP-Pora PLOT | Draw-inject | MS | 115–40 pg mL−1/NM | 2009 | [ |
| Cortisol, dehydroepiandrosterone | Saliva | Supel-Q PLOT capillary column | Draw-inject | MS/MS | 0.9–12 pg mL−1/NM | 2012 | [ |
| Testosterone, cortisol, dehydroepiandrosterone | Saliva | Supel-Q PLOT capillary column | Draw-inject | MS/MS | NM/0.01–0.29 ng mL−1 | 2013 | [ |
| Oxytocin | Saliva | Supel-Q PLOT capillary column | Draw-inject | MS/MS | 4 pg mL−1/NM | 2015 | [ |
| Butanal, pentanal, hexanal, heptanal, octanal and nonanal | Exhaled breath condensate | Graphene/polyaniline (G/PANI) electrodeposited coating | In-valve | UV | 0.02–0.04/0.07–0.13 nmol L−1 | 2015 | [ |
| Butanal, pentanal, hexanal, heptanal, octanal and nonanal | Exhaled breath condensate | Polypyrrole/graphene (PPy/G) composite coating | In-valve | UV | 2.3–3.3/7.7–12.3 nmol L−1 | 2015 | [ |
| Polycyclic aromatic hydrocarbons | Hair | CP-Sil 19CB (14% cyanopropyl phenyl methylsilicone) | In-valve | FLD | 0.5–20.4 pg mL−1/NM | 2015 | [ |
| Heterocyclic amines | Hair | Supel-Q PLOT capillary column | Draw-inject | MS/MS | 0.10–0.78 pg mL−1/NM | 2013 | [ |
1 NM: not mentioned
Figure 4Instrumental configuration of in-tube SPME-MS/MS. (a) Sample extraction on monolithic capillary column, (b) Elution of the analytes by switching the valve position. Adopted from [137] with permissions.
Figure 5LC/MS SIM chromatograms from the analysis of plasma sample spiked with 10 antidepressant drugs after in-tube SPME (Peaks: 1, trazodone; 2, citalopram; 3, amitriptyline; 4, doxepin; 5, paroxetine; 6, clomipramine; 7, imipramine (internal standard); 8, fluvoxamine; 9, sertraline; 10, clozapine; 11, fluoxetine. Adopted from [83] with permissions.
Figure 6Instrumental setup for the determination of fluoroquinolones. Adopted from [147] with permissions.